Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class ASZSE: 002603

Shijiazhuang Yiling Pharmaceutical Co: Net profit grew 7.25% year-over-year in Q1 2025 despite a 6.52% revenue drop

· Issued by Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A

Q1 2025 saw net profit rise 7.25% year-over-year to RMB 325.95 million despite a 6.52% revenue decline, with strong operating cash flow and improved core profitability. Asset impairment and reduced government subsidies were notable headwinds.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A

All Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A news releases